A Phase II multi-center, randomized, double-blind, 24-week, 3-arm, parallel group, placebo-controlled study to investigate the efficacy and safety of RO5285119 in children and adolescents age 5-17 with Autism Spectrum Disorder (ASD)

Administered By

Awarded By

Contributors

Start/End

  • April 13, 2016 - October 31, 2020